NasdaqGM - Delayed Quote • USD
PROCEPT BioRobotics Corporation (PRCT)
At close: May 31 at 4:00 PM EDT
After hours: May 31 at 7:30 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 9 | 9 |
| Avg. Estimate | -0.52 | -0.49 | -1.93 | -1.49 |
| Low Estimate | -0.55 | -0.52 | -1.99 | -1.69 |
| High Estimate | -0.5 | -0.47 | -1.86 | -1.16 |
| Year Ago EPS | -0.56 | -0.51 | -2.24 | -1.93 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 9 | 9 |
| Avg. Estimate | 50.16M | 53.92M | 213.73M | 300.41M |
| Low Estimate | 49.6M | 52.63M | 213.11M | 276.9M |
| High Estimate | 50.99M | 55.1M | 214.67M | 313M |
| Year Ago Sales | 30.46M | 35.1M | 136.19M | 213.73M |
| Sales Growth (year/est) | 64.70% | 53.60% | 56.90% | 40.60% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.57 | -0.51 | -0.44 | -0.56 |
| EPS Actual | -0.56 | -0.51 | -0.54 | -0.51 |
| Difference | 0.01 | 0 | -0.1 | 0.05 |
| Surprise % | 1.80% | 0.00% | -22.70% | 8.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.52 | -0.49 | -1.93 | -1.49 |
| 7 Days Ago | -0.52 | -0.49 | -1.93 | -1.49 |
| 30 Days Ago | -0.52 | -0.5 | -1.94 | -1.5 |
| 60 Days Ago | -0.53 | -0.48 | -2 | -1.52 |
| 90 Days Ago | -0.53 | -0.48 | -2 | -1.51 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 2 | 3 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | PRCT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 7.10% | -- | -- | 8.90% |
| Next Qtr. | 3.90% | -- | -- | 11.40% |
| Current Year | 13.80% | -- | -- | 5.80% |
| Next Year | 22.80% | -- | -- | 12.60% |
| Next 5 Years (per annum) | 21.80% | -- | -- | 11.45% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | TD Cowen: Buy to Buy | 5/6/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 5/6/2024 |
| Maintains | Truist Securities: Buy to Buy | 5/2/2024 |
| Maintains | Truist Securities: Buy to Buy | 2/28/2024 |
| Maintains | Wells Fargo: Overweight to Overweight | 1/9/2024 |
| Maintains | Truist Securities: Buy to Buy | 12/22/2023 |
Related Tickers
RXST RxSight, Inc.
58.47
-1.76%
SWAV Shockwave Medical, Inc.
334.75
0.00%
TMDX TransMedics Group, Inc.
136.40
-0.01%
SGHT Sight Sciences, Inc.
6.56
+0.61%
GKOS Glaukos Corporation
112.72
+1.82%
TMCI Treace Medical Concepts, Inc.
5.88
+2.26%
NARI Inari Medical, Inc.
50.00
-1.36%
OM Outset Medical, Inc.
3.7300
+5.37%
RCEL AVITA Medical, Inc.
9.61
+3.33%
PEN Penumbra, Inc.
189.47
+0.78%